{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:55:10Z","timestamp":1762271710602,"version":"build-2065373602"},"reference-count":10,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,4,15]],"date-time":"2013-04-15T00:00:00Z","timestamp":1365984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2013,6]]},"abstract":"ABSTRACT<\/jats:title>Background<\/jats:title>Preladenant is a selective adenosine A2A<\/jats:sub> receptor antagonist under investigation for Parkinson's disease treatment.<\/jats:p><\/jats:sec>Methods<\/jats:title>A phase 2 36\u2010week open\u2010label follow\u2010up of a double\u2010blind study using preladenant 5 mg twice a day as a levodopa adjunct in 140 subjects with fluctuating Parkinson's disease was conducted. The primary end point was adverse event (AE) assessment. Secondary (efficacy) analyses included hours\/day spent in OFF and ON states and dyskinesia prevalence\/severity.<\/jats:p><\/jats:sec>Results<\/jats:title>The 36\u2010week open\u2010label phase was completed by 106 of 140 subjects (76%). AE\u2010related treatment discontinuations occurred in 19 subjects (14%). Treatment\u2010emergent AEs, reported by \u226515% of subjects, were dyskinesia (33%) and constipation (19%). Preladenant 5 mg twice a day provided OFF time reductions (1.4\u20131.9 hours\/day) and ON time increases (1.2\u20131.5 hours\/day) throughout the 36\u2010week treatment relative to the baseline of the double\u2010blind study.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Long\u2010term preladenant treatment (5 mg twice a day) was generally well tolerated and provided sustained OFF time reductions and ON time increases. \u00a9 2013 Movement<\/jats:italic> Disorder Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.25395","type":"journal-article","created":{"date-parts":[[2013,4,15]],"date-time":"2013-04-15T16:02:43Z","timestamp":1366041763000},"page":"817-820","source":"Crossref","is-referenced-by-count":40,"title":["Long\u2010term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease"],"prefix":"10.1002","volume":"28","author":[{"given":"Stewart A.","family":"Factor","sequence":"first","affiliation":[{"name":"Emory University Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Wolski","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp. Whitehouse Station New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Togasaki","sequence":"additional","affiliation":[{"name":"University of Southern California Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Huyck","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp. Whitehouse Station New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Cantillon","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp. Whitehouse Station New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.W.","family":"Ho","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp. Whitehouse Station New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[{"name":"University of South Florida Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Pourcher","sequence":"additional","affiliation":[{"name":"Laval University Quebec City Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,15]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.212"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(97)01096-5"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2008.12.006"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000095211.71092.A0"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21315"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000313834.22171.17"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70012-6"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20248"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.1.18"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2010.07.011"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25395","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:18:02Z","timestamp":1760951882000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.25395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,15]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1002\/mds.25395"],"URL":"https:\/\/doi.org\/10.1002\/mds.25395","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[2013,4,15]]}}}